US/UK/Canada

Share

Contacts

  • Visiting address

    Norra Stationsgatan 93A, Sweden


    +46 8 697 20 00
  • Gerard Tobin

    Head of Investor Relations


    • Pick a time period -
    Tags ( Active)

    Sobi invites entries to first Sobi Scientific Innovation Awards

    Sobi™ has established the Sobi Scientific Innovation Awards, with a focus on the future of haemophilia care, to recognise innovation and scientific excellence in haemophilia research. Entries will be assessed by an Adjudication Committee of independent, international haemophilia experts, according to scientific credit and contribution to haemophilia, overall concept novelty, as well as the anticipated ability of the research to help liberate life for people with haemophilia. Armin Reininger, Head of Medical and Scientific Affairs at Sobi, says the aim is to focus on research that

    Switching to extended half-life prophylaxis impacted clinical outcomes and improved quality of life for people with haemophilia A or B

    Clinical study data on switching haemophilia A and B patients from on-demand treatment to extended half-life (EHL) prophylaxis showed a positive impact on clinical outcomes, with improvements in quality of life (QoL) and reduced annual bleeding rates (ABR). The results of these joint studies by Sobi™  and Sanofi were presented at ISTH 2019, the 27th Congress of the International Society on Thrombosis and Haemostasis, in Melbourne, Australia, on 7, 8 and 9 July 2019. “This data supports the observation that the introduction of EHLs has allowed for people with

    Interim data evaluating Elocta® for Immune Tolerance Induction in people with inhibitors and severe haemophilia A shared at ISTH 2019

    Interim results from verITI-8, an ongoing prospective, phase 4 study evaluating the efficacy of Elocta® (efmoroctocog alfa), for first-time Immune Tolerance Induction (ITI) for people with severe haemophilia A with inhibitors were presented today. These early data from the joint SobiTM  and Sanofi study in this investigational setting were shared in an oral session at the XXVII Congress of the International Society on Thrombosis and Haemostasis (ISTH). The development of inhibitors, or antibodies, to FVIII replacement therapy is one of the most serious complications

    People with haemophilia and female carriers in Sweden have higher risk of anxiety, depression and pain, based on treatment patterns

    People with haemophilia have an increased risk of acute and chronic pain, and long-term disability, associated with bleeds. Anxiety and depression are other factors negatively affecting their quality of life. These were among the results of the MIND study, which aims to identify patterns of prescribed pain, anti-depressive and anti-anxiety medication and management of pain, depression and anxiety in people with haemophilia in four Nordic countries. The results of the MIND study also show that people with haemophilia in Sweden have a substantially higher prescription of analgesics than

    Sobi presents study data supporting increased possibilities and improved clinical outcomes for people with haemophilia at ISTH

    Sobi™ presents data at the ISTH 2019: The 27th Congress of the International Society on Thrombosis and Haemostasis, Melbourne, Australia, 6 – 10 July 2019, focusing on the use of Elocta® and Alprolix® in clinical settings such as treatment switches from on demand to prophylaxis and immune tolerance induction (ITI). The reported outcomes include annualised bleeding rates, quality of life as well as joint health. It will be the first time interim results from the global, prospective verITI-8 study of rFVIIIFc for first-time ITI will be presented. We will also present data showing the pain and

    Individualised extended half-life factor replacement therapy controls haemostasis in orthopaedic surgery

    Today, Sobi™  and Sanofi will present data demonstrating that Elocta® (efmoroctocog alfa) and Alprolix® (eftrenonacog alfa) can provide perioperative haemostatic control across a wide spectrum of major and minor surgeries in subjects of all ages with severe haemophilia A and B respectively. The presentation will take place at the World Federation of Hemophilia’s 16th International Musculoskeletal Congress (MSK) 10-12 May 2019, in Madrid, Spain. One of the major complications for people living with haemophilia is recurrent bleeding into joints and subsequent

    Sobi™ publishes 2018 Annual and Sustainability Report

    Swedish Orphan Biovitrum AB (publ)  (Sobi™) has released the company’s 2018 Annual and Sustainability Report. The integrated report summarises our business and strategy, financial performance and work on sustainability. “2018 was a year of transformation for Sobi,” says Guido Oelkers, CEO and President. “Our substantial progress in Haemophilia, acquisitions in Immunology and sales growth in Specialty Care mean that the company is essentially, on a pro-forma basis, two-and-a-half times the size it was at the end of 2016. But it is important to understand that we see

    Sobi™ launches Liberate Life™, a vision of living life beyond haemophilia, on World Haemophilia Day

    To mark World Haemophilia Day, Sobi™ is launching Liberate Life™, a vision of living life beyond haemophilia. In a series of long-term commitments, Sobi seeks to shape new standards, optimise treatment, build evidence, create sustainable access and provide community support in haemophilia care. As the first initiative in showcasing the Liberate Life vision, Sobi is reaching out to the broader haemophilia community across Europe through social media, encouraging and motivating people to expect more from life and reach for the many possibilities that advances in care have made possible. An

    New emapalumab data presented at Transplantation and Cellular Therapy (TCT) Meeting highlight post-transplant treatment outcomes in primary HLH

    Swedish Orphan Biovitrum AB (publ)  (Sobi™) (STO:SOBI) and Novimmune SA announced the presentation of late-breaking data from the phase 2/3 clinical study of emapalumab-lzsg in primary haemophagocytic lymphohistiocytosis (HLH) at the 2019 Transplantation and Cellular Therapy (TCT) Meetings, February 20-24 in Houston, Texas. The data examine the outcomes of primary HLH patients who were treated with emapalumab and proceeded to haematopoietic stem cell transplantation (HSCT).

    Sobi publishes the report for the fourth quarter and full-year 2018

    Swedish Orphan Biovitrum AB (publ)  (Sobi™) today announces the results for the fourth quarter and full-year 2018. Total revenues grew 37 per cent compared with Q4 2017 (29 per cent at constant exchange rates (CER)) and amounted to SEK 2,571 M. EBITA was SEK 916 M, an increase of 48 per cent for the quarter, and gross margin amounted to 74 per cent.  Highlights · Total revenues of SEK 2,571 M (1,875) in Q4 and SEK 9,139 M (6,511) for the full year · 37 per cent sales growth in Q4 compared with Q4 2017 (29 per cent at (CER)) · EBITA1increased 48 per cent

    Invitation – Presentation of Sobi’s Q4/FY 2018 results

    On 20 February, at 08:00 CET, Swedish Orphan Biovitrum AB (publ)  (Sobi™) will publish its report for the fourth quarter and full year 2018. Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, on the same day at 14:00 CET. The event will be hosted by Sobi’s CEO and President, Guido Oelkers, and the presentation will be held in English. The presentation can be followed live, or afterwards on www.sobi.com. Slides used in the presentation will be made available on Sobi’s website prior to

    Sobi presents comprehensive study data on extended half-life haemophilia treatments at EAHAD

    Sobi™  will present data at the European Association of Haemophilia and Allied Disorders (EAHAD) conference in Prague, Czech Republic, 6-8 February 2019, showing evidence on the safety, efficacy and long-term benefits of its extended half-life products for the treatment of haemophilia. The studies that will be presented support Sobi’s commitment to develop a treatment paradigm that expand the possibilities and transform life for people with haemophilia. Sobi and our collaboration partner Sanofi will provide interim data on the incidence of inhibitors in previously

    At ASH, extended half-life therapies Elocta® and Alprolix® demonstrate proven efficacy and well-characterised safety over four years

    ASPIRE and B-YOND extension studies show no inhibitor development and consistently low annualised bleeding rates in study participants over four years with Elocta and Alprolix, respectively. Swedish Orphan Biovitrum AB (publ)  (Sobi™) and Bioverativ Inc ., a Sanofi-company, today announced the final results of ASPIRE and B-YOND, the most comprehensive long-term studies of extended half-life factor therapies in haemophilia. The data from both studies confirm the established safety and sustained efficacy of Elocta® (

    Sobi™ to acquire Synagis® US rights from AstraZeneca - creates a platform for global growth

    Sobi™ to acquire Synagis® US rights from AstraZeneca - creates a platform for global growth Swedish Orphan Biovitrum AB (publ)  (Sobi™) (STO:SOBI) has entered into agreements to acquire the perpetual rights to Synagis® (palivizumab) in the US from AstraZeneca and to participate in 50 per cent of the future earnings of the candidate drug MEDI8897 in the US. The total upfront consideration corresponds to USD 1,500 M (SEK 13.6 B[1] 

    Sobi™ publishes the report for the third quarter 2018

    Swedish Orphan Biovitrum AB (publ)  (Sobi™) today announces the results for the third quarter 2018. Total revenues grew 45 per cent compared with Q3 2017 (34 per cent at constant exchange rates (CER)) and amounted to SEK 2,315 M. EBITA was SEK 933 M, an increase of 74 per cent for the quarter, and gross margin amounted to 75 per cent. Continued strong growth in Q3 · Total revenues of SEK 2,315 M (1,601) in Q3 and SEK 6,568 M (4,636) YTD(1) · 45 per cent sales growth in the quarter compared with Q3 2017 (34 per cent at CER) · EBITA increased 74 per cent to

    Sobi™ Cycle bike ride from Mainz to Brussels raises funds, awareness for haemophilia

    Sobi™ Cycle bike ride from Mainz to Brussels raises funds, awareness for haemophilia A team of cyclists from Sobi™ have biked from Mainz to Brussels 2-4 October to help raise funds for people with haemophilia as well as awareness about the condition. SobiCycle 2018 is the third Sobi charity bike ride to raise funds for the European Haemophilia Consortium (EHC). This year the team of Sobi cyclists pedalled from Mainz in Germany to arrive at the EHC Conference 5-7 October in Brussels, Belgium. The three-day bike ride is meeting up with the EHC campaign #thisway, counting down the

    Sobi™ appoints Anne Marie de Jonge Schuermans as Head of Technical Operations

    Swedish Orphan Biovitrum AB (publ) (Sobi™)  has appointed Anne Marie de Jonge Schuermans as Head of Sobi’s new Technical Operations organisation, bringing together Sobi’s Manufacturing Operations/Biological Development & Supply, Quality, Supply Chain, Procurement and Environment & Safety operations. Anne Marie will join on 1 October 2018, and be part of Sobi’s Executive Committee. Anne Marie joins Sobi from Biogen where she served as Vice President for Global Supply Chain Operations & Strategic Partnerships and as an Executive Board Member of Biogen International

    Sobi™ publishes the report for the second quarter 2018

    Swedish Orphan Biovitrum AB (publ)  (Sobi™) today announces the results for the second quarter 2018. Total revenues grew 40 per cent compared with Q2 2017 (36 per cent at constant exchange rates, CER) and amounted to SEK 2,289 M. EBITA was SEK 951 M, an increase of 94 per cent for the quarter, and gross margin amounted to 73 per cent. Q2 outperforms our expectations · Total revenues of SEK 2,289 M (1,639) for Q2 and SEK 4,253 M (3,035) for H1 · 40 per cent sales growth in the quarter compared with Q2 2017 (36 per cent at CER) · EBITA increased by 94 per

    Sobi™ discloses payments to healthcare professionals and healthcare organisations to increase transparency

    Swedish Orphan Biovitrum AB (publ)  (Sobi™) today announces that the company has made all payments and transfers of value to healthcare professionals and organisations from 2017 publicly available*. This includes sponsorships to attend meetings, grants and donations, speaker fees, consultancy and advisory boards in accordance with the European Federation of Pharmaceutical Industries and Associations (EFPIA) Disclosure Code. The information is made available on Sobi´s corporate website , starting 31 May

    Sobi emphasises commitment to haemophilia community at WFH 2018 World Congress

    Recent data show quality-of-life improvements for patients treated prophylactically with Elocta® and Alprolix®, extended half-life haemophilia therapies. Swedish Orphan Biovitrum AB (publ)  (Sobi™)(STO:SOBI) will present data at the World Federation of Hemophilia (WFH) 2018 World Congress, in Glasgow, Scotland, 20-24 May, demonstrating the company’s ongoing commitment to transforming the standard of care for people with haemophilia. Sobi will present real-world data demonstrating improvements in quality-of-life measures, including physical activity and joint pain,

    Sobi™ publishes the report for the first quarter 2018

    Swedish Orphan Biovitrum AB (publ)  (Sobi™) today announces the results for the first quarter 2018. Total revenues grew 41 per cent compared to Q1 2017 and amounted to SEK 1,964 M. EBITA was SEK 771 M, an increase of 90 per cent and gross margin amounted to 72 per cent (74). 2018 off to a strong start · Total revenues of SEK 1,964 M (1,396) · 41 per cent sales growth in the quarter compared to Q1 2017(43 per cent at constant exchange rates, CER) · EBITA increased with 90 per cent to SEK 771 M (406) · Net cash position of SEK 1,744 M (1,472 as of 31

    The Republic of Ireland switches all people with haemophilia A & B treated with replacement clotting factors to Sobi’s™ extended half-life therapies

    The Republic of Ireland has become the first country in Europe where every person with haemophilia will have access to the newest generation of haemophilia treatments, extended half-life therapies, under new supply contracts signed between the HSE (Health Services Executive) and Sobi™.  A new contract for the supply of Elocta® (efmoroctocog alfa), for the treatment of haemophilia A was signed in January 2018. It follows an earlier contract for the supply of Alprolix® (eftrenonacog alfa), for the treatment of haemophilia B. Both Elocta and Alprolix are extended half-

    New data show extended prophylactic dosing with Alprolix® provides safe and effective protection in people with severe haemophilia B

    Post-hoc longitudinal analysis from B-LONG and B-YOND studies shows patients who progressed to individualised prophylactic dosing intervals of 14 days or longer maintained low annualised bleeding rates.Swedish Orphan Biovitrum AB (publ)  (Sobi™)(STO:SOBI) and Bioverativ Inc.  (NASDAQ: BIVVV) today announce the results of a new post-hoc longitudinal analysis demonstrating that individualised dosing with extended half-life therapy, Alprolix® (eftrenonacog alfa), every 14 or more days may be a potential option for people with severe

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe